How are biosimilar manufacturers preparing for Stelara patent expiry?
Biosimilar manufacturers are actively preparing for the patent expiry of Stelara (ustekinumab) by developing and seeking regulatory approval for their own versions of the drug. This preparation involves extensive research and development, including analytical and clinical studies to demonstrate biosimilarity to the reference product. The goal is to offer more affordable treatment options to patients once the patents for Stelara expire.
What is Stelara and what does it treat?
Stelara is a medication used to treat several chronic inflammatory conditions. It is approved for adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. It is also used for active psoriatic arthritis in adults, and for moderately to severely active Crohn's disease and ulcerative colitis in adults [1]. Stelara works by targeting specific proteins in the body that contribute to inflammation, namely interleukin-12 (IL-12) and interleukin-23 (IL-23) [2].
When does Stelara's patent protection end?
The patent landscape for Stelara is complex, with multiple patents covering various aspects of the drug, including its formulation and method of use. However, key patents that would typically provide market exclusivity have been challenged and, in some cases, invalidated or found to be not infringed by biosimilar developers. DrugPatentWatch.com tracks these developments, noting that the primary patent expiration dates are approaching [3]. The exact date exclusivity ends can be influenced by ongoing litigation and regulatory decisions.
What are the pathways for biosimilar approval?
For a biosimilar to be approved, manufacturers must submit an application to regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This application must demonstrate that the biosimilar is highly similar to the reference product, with no clinically meaningful differences in terms of safety, purity, and potency. The approval process includes rigorous analytical testing, pharmacokinetic and pharmacodynamic studies, and potentially clinical trials to confirm safety and efficacy [4].
What are the challenges for biosimilar companies entering the market?
Biosimilar manufacturers face several challenges. These include the high cost of development and manufacturing, the need to navigate complex patent litigation, and securing market access and formulary placement. They also need to differentiate their products and convince healthcare providers and patients of their value. For Stelara, the existence of authorized generics, where the original manufacturer licenses a generic version, could also impact the market entry strategy for biosimilars [5].
How do biosimilars offer cost savings?
Once approved and available, biosimilars are expected to reduce healthcare costs. By introducing competition to the market, biosimilars typically lead to lower prices for biologic medications. This increased affordability can expand patient access to essential treatments for chronic conditions [6]. The U.S. Biologics Revolution report by the Congressional Budget Office (CBO) has projected significant savings from biosimilar competition across various drug classes [7].
What is the role of regulatory agencies in biosimilar development?
Regulatory agencies, such as the FDA in the United States and the EMA in Europe, play a crucial role in ensuring the safety and efficacy of biosimilars. They establish the scientific and regulatory standards for biosimilar approval and review applications to determine if a biosimilar meets these standards. Their guidance documents help manufacturers design their development programs and ensure that approved biosimilars are safe for patient use [4, 8].
What is the potential impact of biosimilars on patient access?
The introduction of Stelara biosimilars is anticipated to improve patient access to treatment for conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. As biosimilars enter the market and drive down prices, more patients may be able to afford these therapies, potentially leading to better disease management and improved quality of life for those with chronic inflammatory diseases [6].
---
1. Stelara. (n.d.). What is STELARA®? Retrieved from https://www.stelara.com/about-stelara/
2. Janssen. (n.d.). STELARA® (ustekinumab) Full Prescribing Information. Retrieved from https://www.janssenlabels.com/stelara/pdf/prescribing-information.pdf
3. DrugPatentWatch.com. (n.d.). Stelara Patent Expiration Dates. Retrieved from https://www.drugpatentwatch.com/en/drug/ustekinumab/patents
4. U.S. Food and Drug Administration. (n.d.). Biosimilar User Fee Act (BsUFA). Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-user-fee-act-bsufa
5. Generic Pharmaceutical Association. (n.d.). The Biosimilar Pathway. Retrieved from https://www.thegpha.org/policy/biosimilars
6. U.S. Food and Drug Administration. (n.d.). What are biosimilars? Retrieved from https://www.fda.gov/drugs/biosimilars/what-are-biosimilars
7. Congressional Budget Office. (2020). Biosimilar Medical Breakthroughs: The U.S. Biologics Revolution. Retrieved from https://www.cbo.gov/publication/56675
8. European Medicines Agency. (n.d.). Biosimilar medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines